Literature DB >> 9786512

Suppression of macrophage inflammatory protein (MIP)-1alpha production and collagen-induced arthritis by adenosine receptor agonists.

C Szabó1, G S Scott, L Virág, G Egnaczyk, A L Salzman, T P Shanley, G Haskó.   

Abstract

1. Ligands of the various adenosine receptor subtypes modulate the production of pro-and anti-inflammatory cytokines. Here we evaluated the effect of adenosine and various ligands of the adenosine receptor subtypes (A1, A2, A3) on the chemokine macrophage inflammatory protein (MIP) 1alpha production in immunostimulated RAW macrophages in vitro. Furthermore, we studied whether a selected A3 adenosine receptor agonist inhibits MIP-1alpha production and affects the course of inflammation in collagen-induced arthritis. 2. In the cultured macrophages, the A3 receptor agonist N6-(3-iodobenzyl)-adenosine-5'-N-methyluronamide (IB-MECA), and, less potently, the A2 receptor agonist 2-p-(2-carboxyethyl) phenethylamino-5'-N-ethyl-carboxamidoadenosine (CGS; 1-200 micro) dose-dependently suppressed the production of MIP-1alpha. The selective A1 receptor agonist 2-chloro-N6-cyclopentyladenosine (CCPA, 1-200 microM) was ineffective, and adenosine was a weak inhibitor. The inhibition of MIP-1alpha production by the A3 and A2 agonist was associated with suppression of its steady-state mRNA levels. 3. Based on the in vitro data, we concluded that activation of A3, and to a lesser extent A2 adenosine receptors suppresses MIP-1alpha expression. Since IB-MECA was the most potent inhibitor of MIP-1alpha expression, we next investigated whether it affects the production of other pro-inflammatory mediators. We observed that IB-MECA (1-300 microM) inhibited, in a dose-dependent manner, the production of IL-12, IL-6, and, to a lesser extent, nitric oxide in the immunostimulated cultured macrophages. 4. Since MIP-alpha is a chemokine which enhances neutrophil recruitment into inflammatory sites, we investigated whether the A3 agonist IB-MECA affects the course of inflammation, MIP-alpha production and the degree of neutrophil recruitment in arthritis. In a model of collagen-induced arthritis in mice, IB-MECA (0.5 mg/kg/day) reduced the severity of joint inflammation. IB-MECA inhibited the formation of MIP-1alpha, IL-12 and nitrotyrosine (an indicator of reactive nitrogen species) in the paws, and suppressed neutrophil infiltration. 5. We conclude that adenosine receptor agonists, most notably the A3 agonist IB-MECA suppress the production of MIP-alpha, and exert anti-inflammatory effects. Therefore, stimulation of adenosine receptor subtypes A3 and A2 may be a strategy worthy of further evaluation for the abrogation of acute or chronic inflammatory disorders.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9786512      PMCID: PMC1565610          DOI: 10.1038/sj.bjp.0702040

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  55 in total

Review 1.  IL-12 as a therapeutic target for pharmacological modulation in immune-mediated and inflammatory diseases: regulation of T helper 1/T helper 2 responses.

Authors:  G Haskó; C Szabó
Journal:  Br J Pharmacol       Date:  1999-07       Impact factor: 8.739

2.  Cyclic AMP-dependent inhibition of human neutrophil oxidative activity by substituted 2-propynylcyclohexyl adenosine A(2A) receptor agonists.

Authors:  G W Sullivan; J M Rieger; W M Scheld; T L Macdonald; J Linden
Journal:  Br J Pharmacol       Date:  2001-03       Impact factor: 8.739

Review 3.  Receptor-mediated interaction between the sympathetic nervous system and immune system in inflammation.

Authors:  G Haskó
Journal:  Neurochem Res       Date:  2001-09       Impact factor: 3.996

4.  Expression and functional role of adenosine receptors in regulating inflammatory responses in human synoviocytes.

Authors:  K Varani; F Vincenzi; A Tosi; M Targa; F F Masieri; A Ongaro; M De Mattei; L Massari; P A Borea
Journal:  Br J Pharmacol       Date:  2010-03-19       Impact factor: 8.739

5.  Adenosine receptor activation ameliorates type 1 diabetes.

Authors:  Zoltán H Németh; David Bleich; Balázs Csóka; Pál Pacher; Jon G Mabley; Leonóra Himer; E Sylvester Vizi; Edwin A Deitch; Csaba Szabó; Bruce N Cronstein; György Haskó
Journal:  FASEB J       Date:  2007-04-03       Impact factor: 5.191

Review 6.  The Purinergic System as a Pharmacological Target for the Treatment of Immune-Mediated Inflammatory Diseases.

Authors:  Luca Antonioli; Corrado Blandizzi; Pál Pacher; György Haskó
Journal:  Pharmacol Rev       Date:  2019-07       Impact factor: 25.468

Review 7.  Role of nonsynaptic communication in regulating the immune response.

Authors:  Zsolt Selmeczy; E Sylvester Vizi; Balázs Csóka; Pál Pacher; György Haskó
Journal:  Neurochem Int       Date:  2007-06-17       Impact factor: 3.921

Review 8.  A(2B) adenosine receptors in immunity and inflammation.

Authors:  György Haskó; Balázs Csóka; Zoltán H Németh; E Sylvester Vizi; Pál Pacher
Journal:  Trends Immunol       Date:  2009-05-07       Impact factor: 16.687

Review 9.  Regulation of macrophage function by adenosine.

Authors:  György Haskó; Pál Pacher
Journal:  Arterioscler Thromb Vasc Biol       Date:  2012-04       Impact factor: 8.311

10.  Inosine protects against the development of diabetes in multiple-low-dose streptozotocin and nonobese diabetic mouse models of type 1 diabetes.

Authors:  Jon G Mabley; Alex Rabinovitch; Wilma Suarez-Pinzon; György Haskó; Pál Pacher; Robert Power; Gary Southan; Andrew Salzman; Csaba Szabó
Journal:  Mol Med       Date:  2003 Mar-Apr       Impact factor: 6.354

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.